The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Sylvester, R. J., van der Meijden, A. P. M., Oosterlinck, W., Witjes, J. A., Bouffioux, C., Denis, L., Newling, D. W. W., & Kurth, K. (2006) · European Urology · doi:10.1016/j.eururo.2005.12.031 · Cited by 3,013
Comprehensive molecular characterization of urothelial bladder carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/za09-dk57 · Cited by 2,990
Receptor Specificity of the Fibroblast Growth Factor Family
Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., & Goldfarb, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15292 · Cited by 1,871
Choi, W., Porten, S., Kim, S., Willis, D., Plimack, E. R., Hoffman-Censits, J., Roth, B., Cheng, T., Tran, M., Lee, I.-L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.009 · Cited by 1,716
World Health Organization Classification of Tumours
Jn, E. (2004) · Medical Entomology and Zoology · Cited by 1,501
Hoadley, K. A., Yau, C., Wolf, D. M., Cherniack, A. D., Tamborero, D., Ng, S., Leiserson, M. D. M., Niu, B., McLellan, M. D., Uzunangelov, V., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.049 · Cited by 1,499
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
Roberts, S. A., Lawrence, M. S., Klimczak, L. J., Grimm, S. A., Fargo, D., Stojanov, P., Kiezun, A., Kryukov, G. V., Carter, S. L., Saksena, G., et al. (2013) · Nature Genetics · doi:10.1038/ng.2702 · Cited by 1,167
Receptor Specificity of the Fibroblast Growth Factor Family
Zhang, X., Ibrahimi, O. A., Olsen, S. K., Umemori, H., Mohammadi, M., & Ornitz, D. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601252200 · Cited by 1,164
Cited by
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
Robertson, A. G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A. D., Hinoue, T., Laird, P. W., Hoadley, K. A., Akbani, R., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.007 · Cited by 2,443
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Necchi, A., Park, S. H., Garcia-Donas, J., Huddart, R., Burgess, E., Fleming, M., Rezazadeh, A., Mellado, B., Varlamov, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817323 · Cited by 1,360
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Patel, V. G., Oh, W. K., & Galsky, M. D. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21631 · Cited by 1,014
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
Lee, S. H., Hu, W., Matulay, J. T., Silva, M. V., Owczarek, T. B., Kim, K., Chua, C. W., Barlow, L. J., Kandoth, C., Williams, A. B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.017 · Cited by 873
Sanli, O., Dobruch, J., Knowles, M. A., Burger, M., Alemozaffar, M., Nielsen, M. E., & Lotan, Y. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.22 · Cited by 814
Self-citationAdvances in bladder cancer biology and therapy
Tran, L., Xiao, J.-F., Agarwal, N., Duex, J. E., & Theodorescu, D. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00313-1 · Cited by 735
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance
Kurtova, A. V., Xiao, J., Mo, Q., Pazhanisamy, S., Krasnow, R., Lerner, S. P., Chen, F., Roh, T. T., Lay, E., Ho, P. L., et al. (2015) · Nature · doi:10.1038/nature14034 · Cited by 578
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 456
Exosome detection via the ultrafast-isolation system: EXODUS
Chen, Y., Zhu, Q., Cheng, L., Wang, Y., Li, M., Yang, Q., Hu, L., Lou, D., Li, J., Dong, X., et al. (2021) · Nature Methods · doi:10.1038/s41592-020-01034-x · Cited by 412
Lindskrog, S. V., Prip, F., Lamy, P., Taber, A., Groeneveld, C. S., Birkenkamp-Demtröder, K., Jensen, J. B., Strandgaard, T., Nordentoft, I., Christensen, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22465-w · Cited by 378
Self-citationvan Hoogstraten, L. M. C., Vrieling, A., van der Heijden, A. G., Kogevinas, M., Richters, A., & Kiemeney, L. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00744-3 · Cited by 375
Pietzak, E. J., Bagrodia, A., Cha, E. K., Drill, E. N., Iyer, G., Isharwal, S., Ostrovnaya, I., Baez, P., Li, Q., Berger, M. F., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.05.032 · Cited by 373
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Matsubara, N., Park, S. H., Huddart, R. A., Burgess, E. F., Houede, N., Banek, S., Guadalupi, V., Ku, J. H., Valderrama, B. P., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308849 · Cited by 340
Hurst, C. D., Alder, O., Platt, F. M., Droop, A., Stead, L. F., Burns, J. E., Burghel, G. J., Jain, S., Klimczak, L. J., Lindsay, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.005 · Cited by 311
Self-citationThe role of tumor microenvironment in therapeutic resistance
Son, B., Lee, S., Youn, H., Kim, E., Kim, W., & Youn, B. (2017) · Oncotarget · doi:10.18632/oncotarget.13907 · Cited by 300
Clonal evolution of chemotherapy-resistant urothelial carcinoma
Faltas, B. M., Prandi, D., Tagawa, S. T., Molina, A. M., Nanus, D. M., Sternberg, C., Rosenberg, J., Mosquera, J. M., Robinson, B., Elemento, O., et al. (2016) · Nature Genetics · doi:10.1038/ng.3692 · Cited by 294
Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors
Tan, T. Z., Rouanne, M., Tan, K. T., Huang, R. Y.-J., & Thiery, J.-P. (2019) · European Urology · doi:10.1016/j.eururo.2018.08.027 · Cited by 277
Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
Dudley, J. C., Schroers-Martin, J., Lazzareschi, D. V., Shi, W. Y., Chen, S. B., Esfahani, M. S., Trivedi, D., Chabon, J. J., Chaudhuri, A. A., Stehr, H., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0825 · Cited by 253
MOGSA: Integrative Single Sample Gene-set Analysis of Multiple Omics Data
(2019) · doi:10.1074/mcp.tir118.001251 · Cited by 78
Hoffmann, M. J., Meneceur, S., Hommel, K., Schulz, W. A., & Niegisch, G. (2021) · Genes · doi:10.3390/genes12020260 · Cited by 28
“A query of public TCGA data for genetic alterations in 413 UC tissues revealed mainly well‐known drivers of UC, like TP53 mutations or RB1 and CDKN2A deletions (Figure 1) [41].”
Background
Metadata
- Authors
- Knowles, M. A., & Hurst, C. D.
- Venue
- Nature Reviews Cancer
- Published
- 2014-12-23
- Volume
- 15
- Issue
- 1
- Pages
- 25-41
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2035297454
- Cited by
- 1,247
- References
- 161
- FWCI
- 16.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.